News
Print
April 27, 2009
ADVAXIS APPLIES FOR APPROXIMATELY $1.0 MILLION WORTH OF GRANTS FROM THE NATIONAL INSTITUTE OF HEALTH
North Brunswick, NJ – April 27, 2009 – Advaxis, Incorporated (OTCBB: ADXS) has met the needed application requirements for approximately $1.0 million worth of grants from the National Institute of Health (NIH) in the development of its Listeria monocytogenes platform.
"The current stimulus package has significantly increased funding for NIH grants," commented Advaxis CEO Thomas A. Moore. "We have been the fortunate recipient of a multitude of NIH grants. We believe the proposals hold great promise."
About Advaxis Vaccines
HER-2 Antigen:
The Company's HER-2 vaccine is based upon a chimeric assembly of many internal and external immune epitopes found to be effective anti-cancer targets. Although never before used therapeutically, this agent follows from work demonstrating efficacy of this agent in a metastatic model of breast cancer in the CNS and published in February 2009. In that work, control animals had a median survival of 25 weeks with complete mortality observed at week 33 but vaccine-treated animals had a median survival of 45 weeks with a 33% survival rate at 50 weeks with 22% of them still tumor free.
HMW-MAA Antigen:
The HMW-MAA research follows from development work that has resulted in patent applications for the use of two different antigens in a single live Listeria vaccine, such that HMW-MAA is used to attack tumor vascular growth while a different antigen is used to attack tumor growth directly.
About the NIH
NIH is the steward of medical and behavioral research for the Nation. Its mission is science in pursuit of fundamental knowledge about the nature and behavior of living systems and the application of that knowledge to extend healthy life and reduce the burdens of illness and disability.
About Advaxis, Incorporated
Based in North Brunswick, New Jersey, Advaxis is developing proprietary Listeria monocytogenes (Lm) cancer vaccines based on technology developed by Dr. Yvonne Paterson, professor of microbiology at the University of Pennsylvania and chairperson of Advaxis’ scientific advisory board. Advaxis is developing attenuated live Lm vaccines that deliver engineered tumor antigens, which stimulate multiple simultaneous immunological mechanisms to fight cancer.
For further information on the Company, please visit: www.advaxis.com.
Forward-Looking Statements
Certain statements contained in this press release are forward-looking statements that involve risks and uncertainties. The statements contained herein that are not purely historical are forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements deal with the Company’s current plans, intentions, beliefs and expectations and statements of future economic performance. Forward-looking statements involve known and unknown risks and uncertainties that may cause the Company's actual results in future periods to differ materially from what is currently anticipated. Factors that could cause or contribute to such differences include those discussed from time to time in reports filed by the Company with the Securities and Exchange Commission. The Company cannot guarantee its future results, levels of activity, performance or achievements.
